Votrient 400mg Tablet (Pazopanib)

Votrient 400mg Tablet is a prescription-based anticancer medicine used in the treatment of advanced kidney cancer (renal cell carcinoma) and certain types of soft tissue sarcoma. The active ingredient of the Votrient is Pazopanib which belongs to the drug class of tyrosine kinase inhibitor. It works by blocking specific enzymes (tyrosine kinases) to control the growth and multiplication of cancer cells. This also blocks the singals that promote the production of new blood vessels that supply nutrition to tumors. Therefore, this action can decrease cancer progression and cancer load. Pazopanib 400mg Tablet is primarily used as a standalone targeted therapy for specific cancers.

The tablet is taken orally and exactly as prescribed by the doctor. The tablet must be swallowed as whole with water and should not be crushed, chewed, or broken. It is usually taken on an empty stomach, at least one hour before or two hours after food. Pazopanib 400mg Tablet is given once daily, and a doctor decides the dose and timings according to the patient's condition, combination therapy, clinical response, and stage of cancer. Patients are advised not to change the dosage because it can lead to severe side effects.

Common side effects include diarrhea, nausea, vomiting, loss of appetite, tiredness, weakness, changes in taste, high blood pressure, hair color changes, and skin or hair changes. A few patients can undergo severe side effects, including severe liver problems, serious bleeding, heart problems, blood clots and severe high blood pressure. Most of the Pazopanib 400mg Tablet side effects can leave when the body adapts to the medicine. However, report to your doctor if you experience serious side effects.

The medicine may harm an unborn baby and should not be used during pregnancy. Patients must list all medicines, supplements, and herbal products that they are taking. The Pazopanib 400mg Tablet must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

kidney cancer

The human body shows undesired symptoms after taking Votrient 400mg Tablet (Pazopanib). Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.

Pazopanib 400mg Tablet (Votrient) is a prescription-based anticancer drug that should be administered orally. It is advised to take this tablet after consulting your healthcare expert. Take this tablet on an empty stomach for better results. Before starting this medicine, please inform your doctor about your medical history.

If you experience any signs and symptoms while taking this medication that are not manageable, do not ignore those symptoms because they may lead to a higher risk.

● Schöffski, P. (2012). Pazopanib in the treatment of soft tissue sarcoma. Expert review of anticancer therapy, 12(6), 711-723.
● Lee, A. T., Jones, R. L., & Huang, P. H. (2019). Pazopanib in advanced soft tissue sarcomas. Signal transduction and targeted therapy, 4(1), 16.
● Hutson, T. E., Davis, I. D., Machiels, J. P. H., De Souza, P. L., Rottey, S., Hong, B. F., ... & Figlin, R. A. (2010). Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 28(3), 475-480.
● Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., ... & Hawkins, R. E. (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of clinical oncology, 28(6), 1061-1068.
● Bukowski, R. M., Yasothan, U., & Kirkpatrick, P. (2010). Pazopanib. Nature reviews Drug discovery, 9(1), 17-18.